Global Dendritic Cell Cancer Vaccine Industry Market

Dendritic Cell Cancer Vaccine Industry Comprehensive Study by Type (CreaVax, Sipuleucel-T (Provenge), Others), Indication (Prostate Cancer, Brain Cancer, Liver Cancer, Others), Distribution Channel (Hospitals, Vaccination Centres, Specialty Clinics, Government Suppliers, Others), End-User (Pediatrics, Adults) Players and Region - Global Market Outlook to 2028

Dendritic Cell Cancer Vaccine Industry Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Dendritic Cell Cancer Vaccine Industry Market Scope
Human tumors express a number of protein antigens that can be recognized by T cells, making them potential targets for cancer immunotherapy. Dendritic cells (DCs) are rare leukocytes that are unique in their ability to present antigens to T cells, a property that has led to their application in cancer therapeutic vaccines. Factors such as increased clinical trial activity related to cancer vaccines, increased demand for mRNA-based vaccines, and the development of cancer therapeutics are positively impacting the growth of the dendritic cell cancer vaccine market.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledGlaxoSmithKline plc (United Kingdom), Activartis (Austria), Argos Therapeutics Inc. (United States), Elios Therapeutics (United States), DanDrit Biotech (United States), Bellicum Pharmaceuticals, Inc. (United States), Medigene AG (Germany), Saint-Gobain Life Sciences, Dendreon Corporation (United States) and Northwest Biotherapeutics (United States)
CAGR%


Key players operating in the dendritic cell cancer vaccine market are undertaking various strategic initiatives such as partnership, collaboration, and new product launches to strengthen their market position. Apart from this, players explore new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.

GlaxoSmithKline plc (United Kingdom), Activartis (Austria), Argos Therapeutics Inc. (United States), Elios Therapeutics (United States), DanDrit Biotech (United States), Bellicum Pharmaceuticals, Inc. (United States), Medigene AG (Germany), Saint-Gobain Life Sciences, Dendreon Corporation (United States) and Northwest Biotherapeutics (United States) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Dendritic Cell Cancer Vaccine Industry market by Type and Region with country level break-up.

On the basis of geography, the market of Dendritic Cell Cancer Vaccine Industry has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2022.

Market Leaders and their expansionary development strategies
In February 2022, BioNTech and Medigene Announce Global Collaboration to Advance T Cell Receptor Immunotherapies Against Cancer.
In June 2018, Northwest Bio-therapeutics secured FDA clearance for its dendritic cell-based vaccine, DCVax-L, utilized to cure glioblastoma cancers.
In the United States, the regulatory authority responsible for approving and regulating vaccines, including dendritic cell cancer vaccines, is the U.S. Food and Drug Administration (FDA). The FDA reviews the safety, efficacy, and manufacturing quality of vaccines through a rigorous regulatory process, which includes preclinical studies, clinical trials, and assessment of manufacturing facilities.

Market Growth Drivers:
Increasing Prevalence of Cancer and Rising Clinical Trial Activity Related to Cancer Vaccines

Challenges:
Stringent Rules and Regulations

Restraints:
Low Availability of Vaccines

Opportunities:
Increased Government Funding for The Development of Cancer Vaccines

Key Target Audience
Vaccine Manufacturers, Government Institutes, Potential Investors, Education & Research Institutes, Regulatory Bodies, Market Research & Consulting Firms and Others

Report Objectives / Segmentation Covered

By Type
  • CreaVax
  • Sipuleucel-T (Provenge)
  • Others
By Indication
  • Prostate Cancer
  • Brain Cancer
  • Liver Cancer
  • Others

By Distribution Channel
  • Hospitals
  • Vaccination Centres
  • Specialty Clinics
  • Government Suppliers
  • Others

By End-User
  • Pediatrics
  • Adults

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Cancer
      • 3.2.2. Rising Clinical Trial Activity Related to Cancer Vaccines
    • 3.3. Market Challenges
      • 3.3.1. Stringent Rules and Regulations
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Dendritic Cell Cancer Vaccine Industry, by Type, Indication, Distribution Channel, End-User and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Dendritic Cell Cancer Vaccine Industry (Value)
      • 5.2.1. Global Dendritic Cell Cancer Vaccine Industry by: Type (Value)
        • 5.2.1.1. CreaVax
        • 5.2.1.2. Sipuleucel-T (Provenge)
        • 5.2.1.3. Others
      • 5.2.2. Global Dendritic Cell Cancer Vaccine Industry by: Indication (Value)
        • 5.2.2.1. Prostate Cancer
        • 5.2.2.2. Brain Cancer
        • 5.2.2.3. Liver Cancer
        • 5.2.2.4. Others
      • 5.2.3. Global Dendritic Cell Cancer Vaccine Industry by: Distribution Channel (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Vaccination Centres
        • 5.2.3.3. Specialty Clinics
        • 5.2.3.4. Government Suppliers
        • 5.2.3.5. Others
      • 5.2.4. Global Dendritic Cell Cancer Vaccine Industry by: End-User (Value)
        • 5.2.4.1. Pediatrics
        • 5.2.4.2. Adults
      • 5.2.5. Global Dendritic Cell Cancer Vaccine Industry Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Dendritic Cell Cancer Vaccine Industry: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline plc (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Activartis (Austria)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Argos Therapeutics Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Elios Therapeutics (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. DanDrit Biotech (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bellicum Pharmaceuticals, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Medigene AG (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Saint-Gobain Life Sciences
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Dendreon Corporation (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Northwest Biotherapeutics (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Dendritic Cell Cancer Vaccine Industry Sale, by Type, Indication, Distribution Channel, End-User and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Dendritic Cell Cancer Vaccine Industry (Value)
      • 7.2.1. Global Dendritic Cell Cancer Vaccine Industry by: Type (Value)
        • 7.2.1.1. CreaVax
        • 7.2.1.2. Sipuleucel-T (Provenge)
        • 7.2.1.3. Others
      • 7.2.2. Global Dendritic Cell Cancer Vaccine Industry by: Indication (Value)
        • 7.2.2.1. Prostate Cancer
        • 7.2.2.2. Brain Cancer
        • 7.2.2.3. Liver Cancer
        • 7.2.2.4. Others
      • 7.2.3. Global Dendritic Cell Cancer Vaccine Industry by: Distribution Channel (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Vaccination Centres
        • 7.2.3.3. Specialty Clinics
        • 7.2.3.4. Government Suppliers
        • 7.2.3.5. Others
      • 7.2.4. Global Dendritic Cell Cancer Vaccine Industry by: End-User (Value)
        • 7.2.4.1. Pediatrics
        • 7.2.4.2. Adults
      • 7.2.5. Global Dendritic Cell Cancer Vaccine Industry Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Dendritic Cell Cancer Vaccine Industry: by Type(USD Million)
  • Table 2. Dendritic Cell Cancer Vaccine Industry CreaVax , by Region USD Million (2017-2022)
  • Table 3. Dendritic Cell Cancer Vaccine Industry Sipuleucel-T (Provenge) , by Region USD Million (2017-2022)
  • Table 4. Dendritic Cell Cancer Vaccine Industry Others , by Region USD Million (2017-2022)
  • Table 5. Dendritic Cell Cancer Vaccine Industry: by Indication(USD Million)
  • Table 6. Dendritic Cell Cancer Vaccine Industry Prostate Cancer , by Region USD Million (2017-2022)
  • Table 7. Dendritic Cell Cancer Vaccine Industry Brain Cancer , by Region USD Million (2017-2022)
  • Table 8. Dendritic Cell Cancer Vaccine Industry Liver Cancer , by Region USD Million (2017-2022)
  • Table 9. Dendritic Cell Cancer Vaccine Industry Others , by Region USD Million (2017-2022)
  • Table 10. Dendritic Cell Cancer Vaccine Industry: by Distribution Channel(USD Million)
  • Table 11. Dendritic Cell Cancer Vaccine Industry Hospitals , by Region USD Million (2017-2022)
  • Table 12. Dendritic Cell Cancer Vaccine Industry Vaccination Centres , by Region USD Million (2017-2022)
  • Table 13. Dendritic Cell Cancer Vaccine Industry Specialty Clinics , by Region USD Million (2017-2022)
  • Table 14. Dendritic Cell Cancer Vaccine Industry Government Suppliers , by Region USD Million (2017-2022)
  • Table 15. Dendritic Cell Cancer Vaccine Industry Others , by Region USD Million (2017-2022)
  • Table 16. Dendritic Cell Cancer Vaccine Industry: by End-User(USD Million)
  • Table 17. Dendritic Cell Cancer Vaccine Industry Pediatrics , by Region USD Million (2017-2022)
  • Table 18. Dendritic Cell Cancer Vaccine Industry Adults , by Region USD Million (2017-2022)
  • Table 19. South America Dendritic Cell Cancer Vaccine Industry, by Country USD Million (2017-2022)
  • Table 20. South America Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2017-2022)
  • Table 21. South America Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2017-2022)
  • Table 22. South America Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2017-2022)
  • Table 23. South America Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2017-2022)
  • Table 24. Brazil Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2017-2022)
  • Table 25. Brazil Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2017-2022)
  • Table 26. Brazil Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2017-2022)
  • Table 27. Brazil Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2017-2022)
  • Table 28. Argentina Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2017-2022)
  • Table 29. Argentina Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2017-2022)
  • Table 30. Argentina Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2017-2022)
  • Table 31. Argentina Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2017-2022)
  • Table 32. Rest of South America Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2017-2022)
  • Table 33. Rest of South America Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2017-2022)
  • Table 34. Rest of South America Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2017-2022)
  • Table 35. Rest of South America Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2017-2022)
  • Table 36. Asia Pacific Dendritic Cell Cancer Vaccine Industry, by Country USD Million (2017-2022)
  • Table 37. Asia Pacific Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2017-2022)
  • Table 38. Asia Pacific Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2017-2022)
  • Table 39. Asia Pacific Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2017-2022)
  • Table 40. Asia Pacific Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2017-2022)
  • Table 41. China Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2017-2022)
  • Table 42. China Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2017-2022)
  • Table 43. China Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2017-2022)
  • Table 44. China Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2017-2022)
  • Table 45. Japan Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2017-2022)
  • Table 46. Japan Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2017-2022)
  • Table 47. Japan Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2017-2022)
  • Table 48. Japan Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2017-2022)
  • Table 49. India Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2017-2022)
  • Table 50. India Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2017-2022)
  • Table 51. India Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2017-2022)
  • Table 52. India Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2017-2022)
  • Table 53. South Korea Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2017-2022)
  • Table 54. South Korea Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2017-2022)
  • Table 55. South Korea Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2017-2022)
  • Table 56. South Korea Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2017-2022)
  • Table 57. Taiwan Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2017-2022)
  • Table 58. Taiwan Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2017-2022)
  • Table 59. Taiwan Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2017-2022)
  • Table 60. Taiwan Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2017-2022)
  • Table 61. Australia Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2017-2022)
  • Table 62. Australia Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2017-2022)
  • Table 63. Australia Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2017-2022)
  • Table 64. Australia Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2017-2022)
  • Table 65. Rest of Asia-Pacific Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2017-2022)
  • Table 66. Rest of Asia-Pacific Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2017-2022)
  • Table 67. Rest of Asia-Pacific Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2017-2022)
  • Table 68. Rest of Asia-Pacific Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2017-2022)
  • Table 69. Europe Dendritic Cell Cancer Vaccine Industry, by Country USD Million (2017-2022)
  • Table 70. Europe Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2017-2022)
  • Table 71. Europe Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2017-2022)
  • Table 72. Europe Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2017-2022)
  • Table 73. Europe Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2017-2022)
  • Table 74. Germany Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2017-2022)
  • Table 75. Germany Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2017-2022)
  • Table 76. Germany Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2017-2022)
  • Table 77. Germany Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2017-2022)
  • Table 78. France Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2017-2022)
  • Table 79. France Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2017-2022)
  • Table 80. France Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2017-2022)
  • Table 81. France Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2017-2022)
  • Table 82. Italy Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2017-2022)
  • Table 83. Italy Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2017-2022)
  • Table 84. Italy Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2017-2022)
  • Table 85. Italy Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2017-2022)
  • Table 86. United Kingdom Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2017-2022)
  • Table 87. United Kingdom Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2017-2022)
  • Table 88. United Kingdom Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2017-2022)
  • Table 89. United Kingdom Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2017-2022)
  • Table 90. Netherlands Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2017-2022)
  • Table 91. Netherlands Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2017-2022)
  • Table 92. Netherlands Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2017-2022)
  • Table 93. Netherlands Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2017-2022)
  • Table 94. Rest of Europe Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2017-2022)
  • Table 95. Rest of Europe Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2017-2022)
  • Table 96. Rest of Europe Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2017-2022)
  • Table 97. Rest of Europe Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2017-2022)
  • Table 98. MEA Dendritic Cell Cancer Vaccine Industry, by Country USD Million (2017-2022)
  • Table 99. MEA Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2017-2022)
  • Table 100. MEA Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2017-2022)
  • Table 101. MEA Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2017-2022)
  • Table 102. MEA Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2017-2022)
  • Table 103. Middle East Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2017-2022)
  • Table 104. Middle East Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2017-2022)
  • Table 105. Middle East Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2017-2022)
  • Table 106. Middle East Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2017-2022)
  • Table 107. Africa Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2017-2022)
  • Table 108. Africa Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2017-2022)
  • Table 109. Africa Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2017-2022)
  • Table 110. Africa Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2017-2022)
  • Table 111. North America Dendritic Cell Cancer Vaccine Industry, by Country USD Million (2017-2022)
  • Table 112. North America Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2017-2022)
  • Table 113. North America Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2017-2022)
  • Table 114. North America Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2017-2022)
  • Table 115. North America Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2017-2022)
  • Table 116. United States Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2017-2022)
  • Table 117. United States Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2017-2022)
  • Table 118. United States Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2017-2022)
  • Table 119. United States Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2017-2022)
  • Table 120. Canada Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2017-2022)
  • Table 121. Canada Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2017-2022)
  • Table 122. Canada Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2017-2022)
  • Table 123. Canada Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2017-2022)
  • Table 124. Mexico Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2017-2022)
  • Table 125. Mexico Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2017-2022)
  • Table 126. Mexico Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2017-2022)
  • Table 127. Mexico Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2017-2022)
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Dendritic Cell Cancer Vaccine Industry: by Type(USD Million)
  • Table 139. Dendritic Cell Cancer Vaccine Industry CreaVax , by Region USD Million (2023-2028)
  • Table 140. Dendritic Cell Cancer Vaccine Industry Sipuleucel-T (Provenge) , by Region USD Million (2023-2028)
  • Table 141. Dendritic Cell Cancer Vaccine Industry Others , by Region USD Million (2023-2028)
  • Table 142. Dendritic Cell Cancer Vaccine Industry: by Indication(USD Million)
  • Table 143. Dendritic Cell Cancer Vaccine Industry Prostate Cancer , by Region USD Million (2023-2028)
  • Table 144. Dendritic Cell Cancer Vaccine Industry Brain Cancer , by Region USD Million (2023-2028)
  • Table 145. Dendritic Cell Cancer Vaccine Industry Liver Cancer , by Region USD Million (2023-2028)
  • Table 146. Dendritic Cell Cancer Vaccine Industry Others , by Region USD Million (2023-2028)
  • Table 147. Dendritic Cell Cancer Vaccine Industry: by Distribution Channel(USD Million)
  • Table 148. Dendritic Cell Cancer Vaccine Industry Hospitals , by Region USD Million (2023-2028)
  • Table 149. Dendritic Cell Cancer Vaccine Industry Vaccination Centres , by Region USD Million (2023-2028)
  • Table 150. Dendritic Cell Cancer Vaccine Industry Specialty Clinics , by Region USD Million (2023-2028)
  • Table 151. Dendritic Cell Cancer Vaccine Industry Government Suppliers , by Region USD Million (2023-2028)
  • Table 152. Dendritic Cell Cancer Vaccine Industry Others , by Region USD Million (2023-2028)
  • Table 153. Dendritic Cell Cancer Vaccine Industry: by End-User(USD Million)
  • Table 154. Dendritic Cell Cancer Vaccine Industry Pediatrics , by Region USD Million (2023-2028)
  • Table 155. Dendritic Cell Cancer Vaccine Industry Adults , by Region USD Million (2023-2028)
  • Table 156. South America Dendritic Cell Cancer Vaccine Industry, by Country USD Million (2023-2028)
  • Table 157. South America Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2023-2028)
  • Table 158. South America Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2023-2028)
  • Table 159. South America Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2023-2028)
  • Table 160. South America Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2023-2028)
  • Table 161. Brazil Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2023-2028)
  • Table 162. Brazil Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2023-2028)
  • Table 163. Brazil Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2023-2028)
  • Table 164. Brazil Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2023-2028)
  • Table 165. Argentina Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2023-2028)
  • Table 166. Argentina Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2023-2028)
  • Table 167. Argentina Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2023-2028)
  • Table 168. Argentina Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2023-2028)
  • Table 169. Rest of South America Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2023-2028)
  • Table 170. Rest of South America Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2023-2028)
  • Table 171. Rest of South America Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2023-2028)
  • Table 172. Rest of South America Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2023-2028)
  • Table 173. Asia Pacific Dendritic Cell Cancer Vaccine Industry, by Country USD Million (2023-2028)
  • Table 174. Asia Pacific Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2023-2028)
  • Table 175. Asia Pacific Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2023-2028)
  • Table 176. Asia Pacific Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2023-2028)
  • Table 177. Asia Pacific Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2023-2028)
  • Table 178. China Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2023-2028)
  • Table 179. China Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2023-2028)
  • Table 180. China Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2023-2028)
  • Table 181. China Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2023-2028)
  • Table 182. Japan Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2023-2028)
  • Table 183. Japan Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2023-2028)
  • Table 184. Japan Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2023-2028)
  • Table 185. Japan Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2023-2028)
  • Table 186. India Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2023-2028)
  • Table 187. India Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2023-2028)
  • Table 188. India Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2023-2028)
  • Table 189. India Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2023-2028)
  • Table 190. South Korea Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2023-2028)
  • Table 191. South Korea Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2023-2028)
  • Table 192. South Korea Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2023-2028)
  • Table 193. South Korea Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2023-2028)
  • Table 194. Taiwan Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2023-2028)
  • Table 195. Taiwan Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2023-2028)
  • Table 196. Taiwan Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2023-2028)
  • Table 197. Taiwan Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2023-2028)
  • Table 198. Australia Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2023-2028)
  • Table 199. Australia Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2023-2028)
  • Table 200. Australia Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2023-2028)
  • Table 201. Australia Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2023-2028)
  • Table 202. Rest of Asia-Pacific Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2023-2028)
  • Table 203. Rest of Asia-Pacific Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2023-2028)
  • Table 204. Rest of Asia-Pacific Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2023-2028)
  • Table 205. Rest of Asia-Pacific Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2023-2028)
  • Table 206. Europe Dendritic Cell Cancer Vaccine Industry, by Country USD Million (2023-2028)
  • Table 207. Europe Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2023-2028)
  • Table 208. Europe Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2023-2028)
  • Table 209. Europe Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2023-2028)
  • Table 210. Europe Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2023-2028)
  • Table 211. Germany Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2023-2028)
  • Table 212. Germany Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2023-2028)
  • Table 213. Germany Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2023-2028)
  • Table 214. Germany Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2023-2028)
  • Table 215. France Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2023-2028)
  • Table 216. France Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2023-2028)
  • Table 217. France Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2023-2028)
  • Table 218. France Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2023-2028)
  • Table 219. Italy Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2023-2028)
  • Table 220. Italy Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2023-2028)
  • Table 221. Italy Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2023-2028)
  • Table 222. Italy Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2023-2028)
  • Table 223. United Kingdom Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2023-2028)
  • Table 224. United Kingdom Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2023-2028)
  • Table 225. United Kingdom Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2023-2028)
  • Table 226. United Kingdom Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2023-2028)
  • Table 227. Netherlands Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2023-2028)
  • Table 228. Netherlands Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2023-2028)
  • Table 229. Netherlands Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2023-2028)
  • Table 230. Netherlands Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2023-2028)
  • Table 231. Rest of Europe Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2023-2028)
  • Table 232. Rest of Europe Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2023-2028)
  • Table 233. Rest of Europe Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2023-2028)
  • Table 234. Rest of Europe Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2023-2028)
  • Table 235. MEA Dendritic Cell Cancer Vaccine Industry, by Country USD Million (2023-2028)
  • Table 236. MEA Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2023-2028)
  • Table 237. MEA Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2023-2028)
  • Table 238. MEA Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2023-2028)
  • Table 239. MEA Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2023-2028)
  • Table 240. Middle East Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2023-2028)
  • Table 241. Middle East Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2023-2028)
  • Table 242. Middle East Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2023-2028)
  • Table 243. Middle East Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2023-2028)
  • Table 244. Africa Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2023-2028)
  • Table 245. Africa Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2023-2028)
  • Table 246. Africa Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2023-2028)
  • Table 247. Africa Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2023-2028)
  • Table 248. North America Dendritic Cell Cancer Vaccine Industry, by Country USD Million (2023-2028)
  • Table 249. North America Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2023-2028)
  • Table 250. North America Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2023-2028)
  • Table 251. North America Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2023-2028)
  • Table 252. North America Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2023-2028)
  • Table 253. United States Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2023-2028)
  • Table 254. United States Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2023-2028)
  • Table 255. United States Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2023-2028)
  • Table 256. United States Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2023-2028)
  • Table 257. Canada Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2023-2028)
  • Table 258. Canada Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2023-2028)
  • Table 259. Canada Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2023-2028)
  • Table 260. Canada Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2023-2028)
  • Table 261. Mexico Dendritic Cell Cancer Vaccine Industry, by Type USD Million (2023-2028)
  • Table 262. Mexico Dendritic Cell Cancer Vaccine Industry, by Indication USD Million (2023-2028)
  • Table 263. Mexico Dendritic Cell Cancer Vaccine Industry, by Distribution Channel USD Million (2023-2028)
  • Table 264. Mexico Dendritic Cell Cancer Vaccine Industry, by End-User USD Million (2023-2028)
  • Table 265. Research Programs/Design for This Report
  • Table 266. Key Data Information from Secondary Sources
  • Table 267. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Dendritic Cell Cancer Vaccine Industry: by Type USD Million (2017-2022)
  • Figure 5. Global Dendritic Cell Cancer Vaccine Industry: by Indication USD Million (2017-2022)
  • Figure 6. Global Dendritic Cell Cancer Vaccine Industry: by Distribution Channel USD Million (2017-2022)
  • Figure 7. Global Dendritic Cell Cancer Vaccine Industry: by End-User USD Million (2017-2022)
  • Figure 8. South America Dendritic Cell Cancer Vaccine Industry Share (%), by Country
  • Figure 9. Asia Pacific Dendritic Cell Cancer Vaccine Industry Share (%), by Country
  • Figure 10. Europe Dendritic Cell Cancer Vaccine Industry Share (%), by Country
  • Figure 11. MEA Dendritic Cell Cancer Vaccine Industry Share (%), by Country
  • Figure 12. North America Dendritic Cell Cancer Vaccine Industry Share (%), by Country
  • Figure 13. Global Dendritic Cell Cancer Vaccine Industry share by Players 2022 (%)
  • Figure 14. Global Dendritic Cell Cancer Vaccine Industry share by Players (Top 3) 2022(%)
  • Figure 15. Global Dendritic Cell Cancer Vaccine Industry share by Players (Top 5) 2022(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2022
  • Figure 19. Activartis (Austria) Revenue, Net Income and Gross profit
  • Figure 20. Activartis (Austria) Revenue: by Geography 2022
  • Figure 21. Argos Therapeutics Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Argos Therapeutics Inc. (United States) Revenue: by Geography 2022
  • Figure 23. Elios Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 24. Elios Therapeutics (United States) Revenue: by Geography 2022
  • Figure 25. DanDrit Biotech (United States) Revenue, Net Income and Gross profit
  • Figure 26. DanDrit Biotech (United States) Revenue: by Geography 2022
  • Figure 27. Bellicum Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Bellicum Pharmaceuticals, Inc. (United States) Revenue: by Geography 2022
  • Figure 29. Medigene AG (Germany) Revenue, Net Income and Gross profit
  • Figure 30. Medigene AG (Germany) Revenue: by Geography 2022
  • Figure 31. Saint-Gobain Life Sciences Revenue, Net Income and Gross profit
  • Figure 32. Saint-Gobain Life Sciences Revenue: by Geography 2022
  • Figure 33. Dendreon Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 34. Dendreon Corporation (United States) Revenue: by Geography 2022
  • Figure 35. Northwest Biotherapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 36. Northwest Biotherapeutics (United States) Revenue: by Geography 2022
  • Figure 37. Global Dendritic Cell Cancer Vaccine Industry: by Type USD Million (2023-2028)
  • Figure 38. Global Dendritic Cell Cancer Vaccine Industry: by Indication USD Million (2023-2028)
  • Figure 39. Global Dendritic Cell Cancer Vaccine Industry: by Distribution Channel USD Million (2023-2028)
  • Figure 40. Global Dendritic Cell Cancer Vaccine Industry: by End-User USD Million (2023-2028)
  • Figure 41. South America Dendritic Cell Cancer Vaccine Industry Share (%), by Country
  • Figure 42. Asia Pacific Dendritic Cell Cancer Vaccine Industry Share (%), by Country
  • Figure 43. Europe Dendritic Cell Cancer Vaccine Industry Share (%), by Country
  • Figure 44. MEA Dendritic Cell Cancer Vaccine Industry Share (%), by Country
  • Figure 45. North America Dendritic Cell Cancer Vaccine Industry Share (%), by Country
List of companies from research coverage that are profiled in the study
  • GlaxoSmithKline plc (United Kingdom)
  • Activartis (Austria)
  • Argos Therapeutics Inc. (United States)
  • Elios Therapeutics (United States)
  • DanDrit Biotech (United States)
  • Bellicum Pharmaceuticals, Inc. (United States)
  • Medigene AG (Germany)
  • Saint-Gobain Life Sciences
  • Dendreon Corporation (United States)
  • Northwest Biotherapeutics (United States)
Select User Access Type

Key Highlights of Report


May 2023 241 Pages 97 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Dendritic Cell Cancer Vaccine Industry Market Quantitative research analysis
Global Dendritic Cell Cancer Vaccine Industry Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Dendritic Cell Cancer Vaccine Industry Market are by type [CreaVax, Sipuleucel-T (Provenge) and Others], by end use application [].
The Dendritic Cell Cancer Vaccine Industry Market is gaining popularity and expected to see strong valuation by 2028.
  • Increasing Prevalence of Cancer
  • Rising Clinical Trial Activity Related to Cancer Vaccines

Know More About Global Dendritic Cell Cancer Vaccine Industry Market Report?

Have a Query? Click Here

Other Related Reports

Drive-through COVID-19 Testing Comprehensive Study by Type (Molecular Test, Antigen Test, Antibody Test), Application (Hospital, Residential area, Workplace, Others), Sample Type (Blood, Nasal swabs...
$ 3800
Next Generation Probiotics Comprehensive Study by Application (Autoimmune Diseases, Glucose Management, Inflammatory Bowel Disease, Others), Category (Akkermansia Muciniphila, Faecalibacterium Prausn...
$ 3800
Medical Manuka Honey Comprehensive Study by Application (Healthcare, Skin Care Industry, Others), Distribution Channel (Online, Offline), Category Type (K-Factor, K-Factor 12, K-Factor 16, K-Factor 2...
$ 3800
Digital Payment in Healthcare Comprehensive Study by Type (On-Premise, Cloud), By Enterprise size (Small size, Medium size, Large size), By Component (Solution, Service, Intelligence), Payment Mode...
$ 3800
Cell Therapy Market Comprehensive Study by Application (Musculoskeletal, Malignancies, Cardiovascular, Dermatology and Wounds, Other), Type (Autologous, Allogeneic), End User (Hospitals, Homecare, S...
$ 3800
Big Data in the Healthcare & Pharmaceutical Industry Comprehensive Study by Application (Financial Analytics, Clinical Data Analytics, Operational Analytics, Population Health Analytics), Deployment ...
$ 3800